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peroxisome proliferator activated receptor β/δ (PPARβ/δ) has pro-angiogenic functions, but whether 
PPARβ/δ modulates endothelial cell metabolism to support the dynamic phenotype remains to be 
established. This study characterised the metabolic response of HUVEC to the PPARβ/δ agonist, 
GW0742, and compared these effects with those induced by VEGF-A. In HUVEC monolayers, flux 
analysis revealed that VEGF-A promoted glycolysis at the expense of fatty acid oxidation (FAO), 
whereas GW0742 reduced both glycolysis and FAO. Only VEGF-A stimulated HUVEC migration and 
proliferation whereas both GW0742 and VEGF-A promoted tubulogenesis. Studies using inhibitors of 
PPARβ/δ or sirtuin-1 showed that the tubulogenic effect of GW0742, but not VEGF-A, was PPARβ/δ- 
and sirtuin-1-dependent. HUVEC were reliant on glycolysis and FAO, and inhibition of either pathway 
disrupted cell growth and proliferation. VEGF-A was a potent inducer of glycolysis in tubulogenic 
HUVEC, while FAO was maintained. In contrast, GW0742-induced tubulogenesis was associated with 
enhanced FAO and a modest increase in glycolysis. These novel data reveal a context-dependent 
regulation of endothelial metabolism by GW0742, where metabolic activity is reduced in monolayers 
but enhanced during tubulogenesis. These findings expand our understanding of PPARβ/δ in the 
endothelium and support the targeting of PPARβ/δ in regulating ec behaviour and boosting tissue 
maintenance and repair.
Endothelial cells (ECs) lining normal vessels remain relatively quiescent, but retain the remarkable ability to 
acquire a highly active and dynamic phenotype following tissue injury or ischaemia1. This is essential for angio-
genesis, during which ECs sprout, migrate and proliferate to establish a new vascular network. Cells undergoing 
such rapid and dynamic alterations in growth and proliferation are known to exhibit significant alterations in 
their metabolism2, so interest in targeting master metabolic regulators, or metabolic pathways directly, to influ-
ence EC behaviour is growing3,4. While the importance of various metabolic pathways for sustaining angiogenic 
behaviour is increasingly recognised3,5, knowledge of how ECs adapt their metabolism in response to extrinsic 
signals is particularly lacking.
Exposure to vascular endothelial growth factor A (VEGF-A), a well-studied angiogenic growth factor, is 
known to increase glycolytic flux in ECs, in part through stimulation of the phosphoinositide 3-kinase (PI3-K)/
Akt signalling pathway and increased activity of key enzymes in the glycolytic cascade6. Characterisation of the 
metabolic response of ECs to other established and putative angiogenic factors, and the functional importance 
of these changes, has not been addressed to date. The peroxisome proliferator activated receptor β/δ (PPARβ/δ) 
nuclear receptor has been identified as a facilitator of the angiogenic response and synthetic PPARβ/δ agonists 
generally exhibit pro-angiogenic activity7–10. PPARβ/δ controls the expression of multiple genes linked to the 
regulation of glucose and lipid homeostasis that, alongside other metabolic regulators, directly impact on cell 
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function11–13. However, knowledge of the metabolic effects of PPARβ/δ activation within the endothelium is cur-
rently limited and largely focused on the pathological microenvironment14. Thus, whether PPARβ/δ acts as a 
metabolic regulator within ECs to support the dynamic phenotype remains to be fully established.
The aim of this study was to characterise the metabolic response of ECs to the highly-selective PPARβ/δ 
agonist, GW074215, and identify its relationship to EC dynamic behaviour. Accordingly, we show that GW0742 
induces a context-dependent metabolic response by ECs, whereby metabolic activity is reduced in cell monolayers 
but elevated, in the form of enhanced fatty acid oxidation (FAO), during dynamic tubulogenesis. Furthermore, we 
identify a requirement for the metabolic co-regulator, sirtuin-1 (SIRT1), in supporting PPARβ/δ’s pro-tubulogenic 
effect. These findings increase our understanding of the role of PPARβ/δ within the endothelium and identify 
PPARβ/δ as a potential regulator governing the metabolic shift during angiogenesis.
Results
GW0742 and VEGF-A induce contrasting metabolic effects in HUVEC monolayers. Confluent 
HUVEC showed a preference for anaerobic glycolysis over that of glucose or FAO when cultured under standard 
conditions (Fig. 1a–c). As expected, HUVEC showed a significantly elevated rate of glycolytic flux following 
treatment with VEGF-A (25 ng/ml) compared with untreated controls, a response associated with increased lac-
tate dehydrogenase A (LDHA) mRNA expression (Fig. 1a,d). A small but significant reduction in the rate of 
FAO (Fig. 1c) was also evident. However, expression of rate-governing enzymes involved in mitochondrial fatty 
Figure 1. GW0742 reduces flux through central metabolic pathways whilst VEGF-A leads to metabolic 
activation in HUVEC monolayers. (a) GW0742 (100 nM; 4 h) significantly reduced, whilst VEGF-A (25 ng/ml; 
4 h) significantly increased, glycolytic flux. (b) No change in D-U-14C-glucose oxidation rate was detected with 
either treatment. (c) Both VEGF-A (25 ng/ml; 5 h) and GW0742 (100 nM; 5 h) treatment reduced FAO. Data 
represent means (±S.E.M) of n = 3 to 5 **p < 0.01 ***p < 0.001 BD = Below level of detection; as determined 
by one-way ANOVA followed by Tukey’s post-comparison test. (d - h) RT-qPCR showing changes in LDHA, 
LDHB, MCT1, CPT1A and CACT mRNA expression in HUVEC monolayers treated with VEGF-A (25 ng/ml; 
4 h) or GW0742 (100 nM; 4 h). Data represent means (±S.E.M) of n = 3 to 5 **p < 0.01 as determined by one-
way ANOVA followed by Tukey’s post-comparison test. (i) GW0742 (100 nM; 4 h) significantly reduces OCR. 
Data represent means (±S.E.M) of n = 4 *p < 0.05 as determined by two-way ANOVA followed by Bonferroni’s 
post-comparison test. Data were collected from 2 independent EC isolates across 2 repeats (j) GW0742 
(100 nM; 4 h) has no effect on mitochondrial reducing potential. Data are means (±S.E.M) of n = 3. (k) Relative 
cellular ATP remains unchanged in HUVEC monolayers following treatment with VEGF-A (25 ng/ml; 4 h) or 
GW0742 (100 nM; 4 h). Data are means (±S.E.M) of n = 3.
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acid uptake (carnitine palmitoyl transferase A (CPT1A) and carnitine acyl-carnitine translocase (CACT)) were 
unaffected (Fig. 1g,h). In contrast, treatment of confluent HUVEC with the PPARβ/δ ligand, GW0742 (100 nM), 
reduced glycolytic flux (Fig. 1a). This was accompanied by a decrease in mRNA expression of the lactate trans-
porter, MCT1, but no change in expression of either of the two LDH isoforms (Fig. 1d–f). 3H2O production from 
3H-palmitate fell below the reliable limit of detection in GW0742-treated cells (Fig. 1c), suggesting that treatment 
with GW0742 may reduce FAO in the contact-inhibited state. In line with this, Seahorse flux analysis showed that 
oxygen consumption rate (OCR) was significantly reduced in GW0742-treated cells (Fig. 1i), whereas CPT1A 
and CACT mRNA expression, as well as the overall reducing capacity of mitochondria (MTT reduction), were 
unchanged (Fig. 1g,h,j). No change in glucose oxidation rate (Fig. 1b) or cellular ATP content (Fig. 1k) was 
detected in either VEGF-A- or GW0742-stimulated cells.
GW0742 but not VEGF-A-induced EC tubulogenesis is dependent on PPARβ/δ. We next con-
firmed that agonist-activated PPARβ/δ stimulates EC dynamic behaviour in vitro. As GW0742 exerts some of 
its effects independently of PPARβ/δ16, the requirement for PPARβ/δ activation was confirmed using GSK0660, 
a PPARβ/δ antagonist. As shown in Fig. 2, incubation with GW0742 (100 nM) did not influence HUVEC migra-
tion, but significantly increased tubulogenesis in the tube formation assay. This response was abolished in the 
presence of a maximally effective concentration of GSK0660 (1 μM) (Fig. 2b and Supplementary Table S1), 
suggesting that the pro-tubulogenic effect of GW0742 was mediated through PPARβ/δ. As expected, VEGF-A 
(25 ng/ml) enhanced both EC migration and tube formation, with the latter being unaffected by treatment with 
GSK0660 (Fig. 2 and Supplementary Table S1), indicating that VEGF-A-induced HUVEC motility is not depend-
ent on PPARβ/δ.
VEGF-A and GW0742 exert differential forms of metabolic activation in motile HUVEC. As in 
HUVEC monolayers, stimulation of tube formation with VEGF-A (25 ng/ml; 4 h) led to a 9-fold increase in glyco-
lytic rate compared with untreated controls (Fig. 3a). In addition, a significant increase in LDHA and MCT1 gene 
expression was apparent at the time that mature EC networks were established (16 h) (Fig. 3d–f). Of note, despite 
the reduced rate of FAO in cell monolayers, FAO in VEGF-A-treated tube-forming cells was maintained (Fig. 3c), 
whilst CPT1A and CACT mRNAs were unaffected (Fig. 3g,h). On the other hand, stimulation of tube formation 
with GW0742 (100 nM) resulted in a significant 2-fold increase in FAO compared to untreated controls (Fig. 3c), 
whilst glycolytic flux was maintained (Fig. 3a). It is interesting to note that although GW0742 increased FAO, a 
significant up-regulation of LDHA mRNA expression was seen in established tubes (16 h) (Fig. 3d), while both 
CACT and CPT1A expression was significantly reduced (Fig. 3g,h). As observed in cell monolayers, glucose oxi-
dation rate was unaffected by VEGF-A or GW0742 treatment (Fig. 3b). To determine if these metabolic changes 
influenced the level of ATP within dynamic cells, change in relative ATP content was assessed. It was not possible 
to assess ATP in the small number of cells used in the tube-formation assay, but a significant increase in ATP 
content was seen in active sub-confluent cells following treatment with VEGF-A but not with GW0742 (Fig. 3i).
The transcriptional response observed in cardiac EC from PPARβ/δ overexpressing mice is 
similar to that elicited in HUVEC by GW0742. To identify whether PPARβ/δ-induced angiogenesis in 
vivo is associated with similar changes in EC metabolic phenotype, cardiac ECs from the previously-reported 
inducible conditional endothelial-specific mouse model of PPARβ/δ overexpression were utilised17. In this model, 
Cre-mediated PPARβ/δ overexpression is induced approximately 3-fold upon treatment with tamoxifen and leads 
to induction of an angiogenic programme within the heart17. RT-qPCR analysis of murine cardiac ECs imme-
diately following their isolation revealed a similar reduction in mRNA expression of genes encoding enzymes 
involved in both glucose (LDHB) and lipid metabolism (CPT1A and CACT) in cells isolated from mice 1 week 
following treatment with tamoxifen (33 mg/kg/day), compared with animals treated with vehicle alone (Fig. 3j). 
These data suggest that in line with the role of PPARβ/δ identified in other tissues11–13, PPARβ/δ-induced angio-
genic activity is associated with a shift in EC metabolic phenotype.
An intact glycolytic network is of greater importance for EC tubulogenesis than mitochondrial- 
derived ATP production. Given the changes to glycolysis and mitochondrial metabolism seen 
in both GW0742- and VEGF-A-treated cells, we next assessed the importance of glycolytic flux and 
mitochondrial-derived ATP production for each agonist in promoting tubulogenic behaviour.
First, using the metabolic flux data reported in Figs. 1 and 3, the potential contribution of mitochondrial 
oxidative phosphorylation (OXPHOS) and glycolysis to ATP production was calculated. In resting HUVEC, 
assuming that 100% of the 14CO2 detected from U-14C-glucose metabolism arose from the TCA cycle, this would 
translate to <50% of calculated ATP production (from the three pathways tested) being supplied through mito-
chondrial OXPHOS (Fig. 4a). However, as studies show that <6% of measured 14CO2 metabolised by ECs arises 
from TCA cycle activity18, the contribution of mitochondrial OXPHOS to ATP production is likely to be even 
lower, with the majority (>70%) instead being supplied through anaerobic glycolysis (Fig. 4a). This is in line with 
that reported by others3. Even when cells were undergoing agonist-induced tubulogenesis, the estimated contri-
bution of mitochondrial-derived ATP remained much lower than that supplied by glycolysis (Fig. 4b).
To directly assess the requirement for a functioning mitochondrial ATP-synthase in fuelling HUVEC dynamic 
activity, we made use of the ATP synthase inhibitor, oligomycin A. Unexpectedly, treatment with oligomycin A 
(2 μM; 16 h) led to a significant and robust induction of tube formation, comparable to that induced by the other 
two agonists (Fig. 4c and Supplementary Table S2). When oligomycin A was combined with VEGF-A, no inhib-
itory or additive effects were evident. However, when GW0742 and oligomycin A were combined, the number of 
tubes formed was still significantly greater than in control conditions, but other parameters measured, such as the 
number of junctions, were not (see Supplementary Table S2). These data indicate that ATP production through 
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mitochondrial ATP synthase is not a fundamental requirement for supporting HUVEC dynamic behaviour in 
vitro, particularly in the presence of VEGF-A. However, impedance of mitochondrial ATP synthase activity may 
partially disrupt the actions of GW0742 in terms of connectivity of formed tubes but not overall tube number.
In contrast, when glycolytic flux was suppressed using the 6-phosphofructo-2-kinase/fructose-2,6- 
biphosphatase 3 (PFKFB3) inhibitor, 3PO (15 μM)3,19, HUVEC were unable to form capillary-like structures after 
stimulation with either VEGF-A (25 ng/ml) or GW0742 (100 nM) (see Supplementary Fig. S1), and a complete 
cytostatic effect was observed in the presence of the PFKFB3 inhibitor. However, HUVEC, in both the tube for-
mation assay and in monolayers, were still capable of reducing MTT, indicating that a degree of mitochondrial 
function was retained under these conditions. Furthermore, in cell monolayers, exposure to 3PO (15 μM; 16 h) 
was associated with a 15% reduction in mitochondrial reducing potential (see Supplementary Fig. S1), suggesting 
that 3PO treatment may lead to an overall reduction in metabolic activity.
As an alternative means of reducing glycolytic flux, HUVEC were co-incubated with 10 mM exogenous 
L-lactate, a concentration sufficient to reduce glycolytic flux in HUVEC monolayers (see Supplementary Fig. S2). 
The presence of exogenous L-lactate led to a significant reduction in VEGF-A-induced tube formation but did not 
Figure 2. GW0742 induces HUVEC tubulogenesis in a PPARβ/δ-dependent manner. (a) VEGF-A (25 ng/
ml), but not GW0742 (100 nM), significantly increased HUVEC migration in a scratch assay (16 h). Data 
represent mean (±S.E.M) % migration (n = 3); *p < 0.05 vs. untreated control as determined by one-way 
repeated measures ANOVA followed by Bonferroni’s post-comparison test. (b) GW0742 (100 nM), but not 
VEGF-A (25 ng/ml), induced capillary-like tube formation is significantly reduced in the presence of GSK0660 
(1 µM) (n = 6). Data represent mean (±S.E.M) number of branches/field; ****p < 0.0001 vs. untreated control; 
###p < 0.001; &p < 0.05 vs. GSK0660 control; as determined by two-way repeated measures ANOVA followed by 
Bonferroni’s post-comparison test. (c) Representative images of capillary-like structures induced by GW0742 
(100 nM) and VEGF-A (25 ng/ml) at 16 h in the absence or presence of GSK0660 (1 µM).
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affect GW0742-induced tubulogenesis (Fig. 4d and Supplementary Fig. S2 & Table S3). Moreover, L-lactate alone 
induced dynamic tube formation. A reduced lactate concentration in the medium (from 10 to approximately 
5 mM) at the end of the assay (16 h), suggests that this positive motile effect was associated with the direct uptake 
of L-lactate by HUVEC (see Supplementary Fig. S2). Although glucose oxidation was significantly reduced in 
cells undergoing L-lactate-induced tubulogenesis versus untreated control cells, interestingly the rate of glyc-
olysis was maintained, and a cytostatic effect was still observed in the presence of the glycolysis inhibitor, 3PO 
(see Supplementary Fig. S2). When LDH was directly inhibited with oxamate (1 mM), a structural analogue of 
pyruvate, this reduced HUVEC tubulogenesis under basal, VEGF-A, GW0742, and L-lactate treated conditions 
(Fig. 4e and Supplementary Fig. S3 & Table S4), suggesting that an active LDH enzyme is essential for supporting 
HUVEC dynamic behaviour, independent of the stimulus.
Mitochondrial FAO contributes to growth factor-induced EC growth and motility. Although not 
a major contributor to EC ATP production, a healthy and functional mitochondrial network is vital for efficient 
Figure 3. GW0742 and VEGF-A enhance flux through central metabolic pathways in dynamic HUVEC. 
(a) VEGF-A (25 ng/ml; 4 h), but not GW0742 (100 nM; 4 h), treatment significantly increased glycolytic flux. 
(b) No change in D-U-14C-glucose oxidation rate was detected with either treatment. (c) GW0742 (100 nM; 
5 h), but not VEGF-A (25 ng/ml; 5 h), treatment significantly increased FAO. Data are means (±S.E.M) of 
n = 3–5; *p < 0.05 **p < 0.01 vs. untreated control as determined by one-way ANOVA followed by Tukey’s 
post-comparison test. (d - h) RT-qPCR showing changes in LDHA, LDHB, MCT1, CPT1A and CACT mRNA 
expression in tubulogenic HUVEC treated with VEGF-A (25 ng/ml; 4 h) or GW0742 (100 nM; 4 h). Data show 
means (±S.E.M) of n = 3–5 *p < 0.05 **p < 0.01 ***p < 0.001 as determined by one-way ANOVA followed by 
Tukey’s post-comparison test. (i) Relative cellular ATP level is significantly increased in sub-confluent HUVEC 
treated with VEGF-A but not GW0742. Data are means (±S.E.M) of n = 3 **p < 0.01 as determined by one-way 
ANOVA followed by Tukey’s post-comparison test. (j) RT-qPCR for metabolic genes in mouse cardiac ECs from 
control (Tie2-CreERT2 + Tamoxifen; n = 5) or EC-selective tamoxifen-inducible PPARβ/δ overexpressing (Tie2-
CreERT2;PPARβ/δ; n = 5) animals treated with tamoxifen compared to Tie2-CreERT2;PPARβ/δ animals (n = 5) 
treated with vehicle. Data are means (±S.E.M); *p < 0.05 vs. Tie2-CreERT2;PPARβ/δ + vehicle and #p < 0.05 
vs. Tie2-CreERT2 + tamoxifen; as determined by one-way ANOVA followed by Tukey’s post-comparison test. 
Numbers above bars indicate p-values.
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Figure 4. Mitochondrial ATP synthesis contributes less than glycolysis to HUVEC ATP production and is not 
essential for HUVEC tubulogenesis. (a) Glycolysis (Gly), compared with glucose oxidation (GO) and FAO, 
provides most of the estimated ATP under basal contact-inhibited conditions when assuming either 100% 
or 6% of the 14CO2 detected from D-U-14C-glucose metabolism arises from the TCA cycle. (b) Glycolysis, 
compared with glucose oxidation and FAO, is the largest contributor to estimated ATP production rate in 
dynamic HUVEC under basal, VEGF-A (25 ng/ml) and GW0742 (100 nM) treated conditions when assuming 
6% of the 14CO2 detected from D-U-14C-glucose metabolism arises from the TCA cycle. (c) Inhibition of 
mitochondrial ATP synthase with oligomycin A (2 µM) lead to a significant increase in the number of capillary-
like tubes formed by HUVEC at 16 h and had no significant effect on VEGF-A (25 ng/ml) or GW0742 (100 nM) 
induced tubulogenesis. Data are means (±S.E.M) number of branches/field from n = 3. *p < 0.05 **p < 0.01 vs. 
untreated control; ##p < 0.01; as determined by two-way repeated measures ANOVA followed by Bonferroni’s 
post-comparison test. (d) L-lactate (10 mM) significantly increased the number of capillary-like structures 
formed by HUVEC at 16 h and significantly reduced VEGF-A (25 ng/ml), but not GW0742 (100 nM)-induced 
tube formation. Data represent means (±S.E.M) of n = 6; **p < 0.01 vs. untreated control; #p < 0.05 ##p < 0.01; 
as determined by two-way repeated measures ANOVA followed by Bonferroni’s post-comparison test. (e) 
Direct inhibition of LDH with oxamate (1 mM) lead to significant reduction in capillary-like tube formation 
by HUVEC at 16 h under basal, VEGF-A (25 ng/ml), GW0742 (100 nM) and L-lactate (10 mM) conditions. 
Data represent mean (±S.E.M) number of branches/field from n = 5. **p < 0.01 ****p < 0.0001 vs. untreated 
control; ####p < 0.0001; as determined by two-way repeated measures ANOVA followed by Bonferroni’s post-
comparison test.
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cell growth and function. In ECs, VEGF-A has been shown to stimulate mitochondrial biogenesis20 and since 
studies have demonstrated that PPARβ/δ can facilitate mitochondrial biogenesis in other cell types21, the effects 
of GW0742 and VEGF-A on mitochondrial biogenesis/dynamics were investigated.
Treatment of confluent HUVEC with VEGF-A (25 ng/ml; 4 h) was not associated with any significant change 
in mRNA expression of mitochondrial transcription factor A (TFAM), a transcription factor involved in mito-
chondrial biogenesis, or the mitochondrial fusion protein 2 (MFN2) (see Supplementary Fig. S4). However, 
VEGF-A treatment did result in a significant increase in relative mitochondrial DNA content (p = 0.02), as meas-
ured by qPCR, and a subtle change in mitochondrial morphology and number by visual inspection following 
incubation with MitoTracker Green (see Supplementary Fig. S4). No change in either TFAM mRNA expression, 
mitochondrial DNA content, or MitoTracker Green staining was detected following treatment with GW0742 
(100 nM; 4 h) (see Supplementary Fig. S4). However, after VEGF-A and GW0742-induced tube formation (16 h), 
mitochondria appeared more aligned within the tubes and there was an increase in MFN2 mRNA expression (see 
Supplementary Fig. S4), suggesting a common change in mitochondrial tethering upon HUVEC tubulogenesis.
It has recently been suggested that mitochondrial FAO is optimised to uniquely supply carbon for the synthe-
sis of nucleotides necessary for EC proliferation5. As an elevated rate of FAO was observed in GW0742-induced 
tubulogenic cells (see Fig. 3c), the effect of GW0742 treatment on HUVEC proliferation was assessed.
As expected, VEGF-A (25 ng/ml) significantly enhanced HUVEC proliferation at 24 h, as assessed by BrdU 
incorporation (Fig. 5a,b) and nuclear counting (Supplementary Fig. S5), whereas treatment with GW0742 
(100 nM) had no effect. To understand the importance of mitochondrial FAO for VEGF-A-induced HUVEC 
proliferation, siRNA was used to achieve targeted knock-down of CPT1A. Immunofluorescence imaging 
showed effective silencing of CPT1A was achieved at a siRNA concentration of 10 nM using two independ-
ent siRNAs (Fig. 5c). This was also confirmed by RT-qPCR (for siRNA 1 & 2) and western blot (for siRNA 1 
Figure 5. VEGF-A but not GW0742 promotes HUVEC proliferation which requires an intact FAO pathway. (a) 
VEGF-A (25 ng/ml) but not GW0742 (100 nM) significantly increased HUVEC proliferation (24 h), as assessed 
by BrdU incorporation. Data represent mean (±S.E.M) percentage of BrdU+ cells from n = 3; *p < 0.05 vs. 
untreated control as determined by one-way repeated measures ANOVA followed by Tukey’s post-comparison 
test. (b) Representative images showing BrdU incorporation following control, VEGF-A (25 ng/ml) or GW0742 
(100 nM) treatment for 24 h. (c) Representative Immunofluorescence images showing a significant reduction 
in CPT1A expression 48 h following transfection with CPT1A-targeting siRNA sequences (10 nM). (d) VEGF-
A-induced (25 ng/ml; 24 h) proliferation (BrdU incorporation) was significantly reduced in CPT1A-silenced 
HUVEC. Data represent means (±S.E.M) of n = 3. **p < 0.01 as determined by two-way ANOVA followed by 
Bonferroni’s post-comparison test. (e) PPARβ/δ mRNA expression is significantly reduced in CPT1A-silenced 
cells 48 h post-transfection (n = 3). Data represent means (±S.E.M); *p < 0.05 vs. non-coding transfection 
control as determined by one-way ANOVA followed by Bonferroni’s post-comparison test.
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only) (Supplementary Fig. S5). The increase in HUVEC proliferation in response to VEGF-A (25 ng/ml; 24 h) 
was still evident in cells transfected with non-coding siRNA (10 nM), as assessed by BrdU incorporation, but 
was abolished in CPT1A-silenced HUVEC (Fig. 5d and Supplementary Fig. S5), supporting a role for FAO in 
VEGF-A-induced HUVEC proliferation.
As the PPARβ/δ agonist did not affect HUVEC proliferation, the importance of mitochondrial FAO for 
HUVEC growth into capillary-like branches was investigated. Although siRNA against CPT1A successfully 
reduced CPT1A expression, PPARβ/δ mRNA expression was also significantly down-regulated in cells where 
CPT1A had been silenced (Fig. 5e). This effect was observed following silencing with both CPT1A-targeting 
siRNAs, suggesting an intricate relationship between CPT1A-governed FAO and PPARβ/δ expression, making 
it difficult to decipher if any functional effect on GW0742-induced tubulogenesis reflects a reduction in CPT1A 
activity or the associated reduction in PPARβ/δ expression.
To avoid the problem with CPT1A silencing, we then used a pharmacological approach employing the generic 
CPT1 inhibitor, etomoxir (ETO). ETO is widely used at concentrations of 40 μM or higher4. However, the pres-
ence of 40 μM ETO in the tube-formation assay led to significant cell death, as indicated by the detachment of 
cells from the substratum. In subsequent investigations using ETO at 1 and 10 μM, a varied response by individual 
HUVEC isolates was observed. In some cases, the presence of ETO at either concentration led to significant cell 
detachment from the matrix, whilst in other isolates, ETO had no effect on basal tube-formation but reduced 
the number of tube-like branches formed under both agonist-treated conditions after 16 h (see Supplementary 
Fig. S6).
Although it was not possible to reliably confirm a role for FAO in agonist-induced tubulogenesis, these data 
suggest that disruption of FAO for a prolonged period can significantly disrupt EC growth and proliferation.
GW0742 but not VEGF-A-induced tubulogenesis is dependent on the metabolic co-regulator 
SIRT1. PPARβ/δ-mediated effects have been reported to be SIRT1-dependent22, and SIRT1 itself has recently 
been linked to the metabolic regulation of angiogenesis through a mechanism involving deacetylation of the 
FOXO1 transcription factor23–25. This prompted us to investigate the role of the SIRT1/FOXO1 axis in facilitating 
GW0742-induced tube formation.
As indicated in Supplementary Fig. S6, immunofluorescence staining showed that SIRT1 was predominantly 
located within the nuclear and perinuclear region of HUVEC when cultured as contact-inhibited monolayers. 
Importantly, SIRT1 maintained its nuclear location upon stimulation to form tube-like structures with either 
GW0742 (100 nM) or VEGF-A (25 ng/ml). No significant increase in SIRT1 mRNA expression was observed 
under any treatment condition, either in HUVEC monolayers or following tubulogenesis (see Supplementary 
Fig. S7). When SIRT1 activity was inhibited using the highly-selective inhibitor, Ex-527 (1 μM), GW0742-induced 
tube formation was significantly reduced, whereas basal and VEGF-A-driven tubulogenesis were unaffected 
(Fig. 6a and Supplementary Table S5).
To identify whether the SIRT1-dependency of GW0742’s effect on tube formation was due to the requirement 
for SIRT1-mediated regulation of FOXO1, the acetylation status of FOXO1 was investigated. Immunofluorescence 
microscopy using an antibody specific for acetylated FOXO1 (acFOXO1) showed that the acetylated form of this 
transcription factor was almost exclusively located within the nuclear compartment of HUVEC and that the 
degree of acetylation was not influenced by either GW0742 (100 nM; 1 h) or VEGF-A (25 ng/ml; 1 h) (Fig. 6b and 
Supplementary Fig. S7). As VEGF-A is known to rapidly (within 1 h post-stimulation) inactivate FOXO1 through 
Akt-mediated phosphorylation26,27, the phosphorylation status of FOXO1 (pFOXO1) was measured in parallel. 
As expected, treatment of confluent HUVEC with VEGF-A (25 ng/ml; 1 h) led to an increase in FOXO1 phos-
phorylation, as assessed by western blotting, while incubation with GW0742 (100 nM; 1 h) did not affect FOXO1 
phosphorylation status (Fig. 6c,d).
Together these data show that SIRT1 is predominantly located within the nucleus of endothelial cells and that 
whilst VEGF-A leads to FOXO1 inactivation and SIRT1-independent HUVEC tubulogenesis, GW0742-induced 
HUVEC tubulogenesis is a SIRT1-dependent process but independent of any significant change in FOXO1 status.
Discussion
The importance of metabolism for regulating angiogenic behaviour is increasingly recognised3,5 but knowledge 
of how ECs adapt their metabolism in response to extrinsic signals is still lacking. Although a pro-angiogenic role 
for the PPARβ/δ nuclear receptor has been demonstrated7,10,17, whether this effect is mediated through alterations 
in EC metabolism has not been thoroughly investigated. We therefore aimed to compare the functional and met-
abolic responses of HUVEC treated with the pharmacological PPARβ/δ agonist, GW0742, with that of VEGF-A 
which has well-established proliferative, migratory and tubulogenic effects28.
The results presented here suggest that unlike VEGF-A, treatment of HUVEC with a selective concentration 
of GW0742 (100 nM)15 is not sufficient to induce short-term proliferation or migration. In line with this, it has 
been reported that GW0742 fails to induce proliferation of human retinal microvascular ECs at 24 h10, and sim-
ilar results have also been described with the alternative PPARβ/δ agonist, GW50151629,30. This contrasts with 
findings reported by others demonstrating pro-proliferative and pro-migratory effects of PPARβ/δ agonists on 
ECs7,31,32. These discrepancies may reflect the time-point analysed, as the pro-proliferative effects were principally 
observed following long-term treatment (3–14 days) as opposed to the 24 h time point analysed here.
The contrasting functional responses of HUVEC to GW0742 and VEGF-A stimulation may be explained 
in part through the differential metabolic response induced by these two agonists. VEGF-A activates multiple 
signalling pathways that can lead to an increased rate of glycolysis and induction of mitochondrial biogenesis 
in preparation for cell proliferation3,20, a response also observed in the present study in HUVEC monolayers. 
Increased glycolytic flux can support migratory behaviour as many glycolytic enzymes are located alongside 
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cytoskeletal proteins, providing hotspots of localised ATP production3. A high level of glycolysis also supports 
proliferation, as flux through glycolysis and its associated side-pathways provides the carbon necessary for the 
generation of new biomass33,34.
In contrast, treatment of HUVEC monolayers with GW0742 caused a reduction in glycolysis, FAO and oxygen 
consumption, indicating that PPARβ/δ may instead facilitate a form of metabolic quiescence. Importantly, this 
response was not associated with a compromise in overall mitochondrial activity, as no changes in mitochon-
drial DNA content, MitoTracker staining or MTT reducing capacity were observed, and cellular ATP content 
remained stable. This phenotype could, in part, contribute to the known anti-inflammatory and cyto-protective 
effects of PPARβ/δ agonists within the vasculature35–38, as a less active metabolism could be a mechanism by 
which ECs afford further protection from unnecessary oxidative stress arising from mitochondrial ROS pro-
duction39. Furthermore, lowered EC metabolic rate could optimise nutrient transfer through the endothelium, 
thereby facilitating the delivery of nutrients to underlying tissues, as has been indicated in the heart40. It is tempt-
ing to speculate that these metabolic effects may contribute to the perceived benefits exerted by PPARβ/δ agonists 
on reperfusion-induced injury41–43. Interestingly, the metabolic response following GW0742 treatment demon-
strated here is similar to that described for other vascular protective stimuli25,44, suggesting that this may be a 
common cyto-protective mechanism.
Whilst migration and proliferation were unaffected by GW0742 treatment, both GW0742 and VEGF-A were 
able to exert a tubulogenic effect. Similar pro-angiogenic responses to PPARβ/δ activation have been reported 
previously7–10,17. Furthermore, we now show that this tubulogenic effect is dependent on the deacetylase enzyme 
and metabolic co-regulator, SIRT1. SIRT1 signalling has previously been linked with regulating mitochondrial 
FAO45, as well as co-ordinating angiogenic activity, with SIRT1-silenced HUVEC showing a reduction in PDGF-β 
expression23,24, a key mediator in the recruitment of mural cells necessary for vessel stabilisation46. Given the lack 
of effect of the PPARβ/δ agonist on EC migration and proliferation, it seems reasonable to propose that PPARβ/δ 
may co-operate alongside SIRT1 within the nuclear compartment to regulate neo-vessel maturation/stabilisation.
It is possible that several SIRT1 target proteins are involved in facilitating the tubulogenic response23,24,47. One 
such target is the FOXO1 transcription factor which also plays a vital role in the regulation of EC metabolism 
and in the maturation/stabilisation phase of angiogenesis25. However, the absence of any significant change in 
Figure 6. GW0742-induced HUVEC tubulogenesis is SIRT1-dependent, but independent of any change in 
FOXO1 activation status (a) GW0742 (100 nM), but not VEGF-A (25 ng/ml), mediated tube formation was 
significantly reduced in the presence of the selective SIRT1 inhibitor, Ex-527 (1 µM), at 16 h. Data represent 
mean (±S.E.M) number of branches/field from n = 3. *p < 0.05 vs. untreated control; #p < 0.05; &p < 0.05 vs. Ex-
527 control; as determined by two-way repeated measures ANOVA followed by Bonferroni’s post-comparison 
test. (b) FOXO1 acetylation status was not changed following treatment (1 h) with either VEGF-A (25 ng/
ml) or GW0742 (100 nM). Data represents means (±S.E.M) from n = 3. For each n number, fluorescence 
intensity was analysed from 150 cells per treatment condition. (c) Densitometry analysis showing that FOXO1 
phosphorylation is not significantly changed following treatment (1 h) with GW0742 (100 nM) (n = 3) but is 
significantly increased following treatment (1 h) with VEGF-A (25 ng/ml) (n = 2) compared to untreated control 
(n = 3). Data represent means (±S.E.M). *p < 0.05 vs. untreated control as determined by one-way ANOVA 
followed by Bonferroni’s post-comparison test. (d) Representative western blot showing phosphorylated 
FOXO1, total FOXO1 and β-actin loading control. Boxed areas indicate non-adjacent lanes on the original blot 
(see Supplementary Fig. S8).
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acetylation or phosphorylation with GW0742 treatment suggests that FOXO1 is unlikely to be a major target in 
this instance. Given that only a short time-point was investigated, involvement of FOXO1 at a later time-point 
cannot be ruled out.
Vessel maturation may also be supported through alterations in mitochondrial FAO. FAO has been shown 
to be required for the establishment of stable networks on MatrigelTM through facilitating EC-EC contact and 
regulating permeability4. In keeping with this, SIRT1-dependent GW0742-induced tubulogenesis was associated 
with an increased rate of FAO, a response not seen with exposure to VEGF-A. Unexpectedly, however, by 16 h 
of tubulogenesis in the presence of GW0742, both CACT and CPT1A genes had become down-regulated. This 
profile was also evident in cardiac ECs isolated from mice with selective endothelial PPARβ/δ overexpression, 
a model characterised by enhanced angiogenesis within the heart17. Although we cannot exclude that mouse 
cardiac ECs may have a slightly different metabolic response to that of HUVEC, the data for both cell types are 
in close agreement with each other. As such, this down-regulation of gene expression at the latter stages of both 
GW0742-induced HUVEC tubulogenesis in vitro and PPARβ/δ-induced angiogenesis in vivo may indicate a reg-
ulatory feedback loop designed to prevent a persistently elevated rate of FAO that could lead to a disturbance 
in local metabolic homeostasis. Indeed, rather than the physiological cardiac hypertrophy observed with the 
PPARβ/δ agonist, endothelial-specific PPARβ/δ overexpressing mice develop a pathological cardiac hypertrophy 
that was suggested to be a consequence of an altered balance of PPARβ/δ activity between the vascular and mus-
cular compartments8,17.
Although an induction of FAO by PPARβ/δ activation has been established, its functional role remains 
unclear. Despite respiration in ECs being highly coupled with ATP synthesis48, increasing FAO to fuel 
mitochondrial-derived ATP does not appear to be a primary factor, as incubation with oligomycin, an inhibitor 
of mitochondrial ATP synthase, did not significantly impair the ability of HUVEC to form tube-like structures. 
This is in line with the fact that ECs principally obtain their ATP through glycolysis3. Moreover, an increase in 
tube-formation at 16 h of oligomycin treatment was evident, likely because of a compensatory increase in glyco-
lytic flux that is known to occur following ATP synthase inhibition48. When coupled with the basal level of stim-
ulation provided by the matrix, this adaptation may be enough to induce HUVEC tubulogenesis in vitro. Reports 
also present the possibility of oligomycin-induced VEGF production49. However, this effect was described in 
a monocytic cell line and further investigation would be required to determine whether similar mechanisms 
are operative in ECs. Beyond ATP production, fatty acids offer a rich source of carbon beneficial for generating 
biomass. ECs appear to be one of only a few cell types to utilise FAO for supplying carbon to support nucleotide 
synthesis vital for proliferation5. Although this role for FAO has yet to be confirmed by others, in support of 
such a concept, the VEGF-A-induced proliferation reported in the current study was completely abolished in 
CPT1A-silenced HUVEC. However, it is unlikely that the increase in FAO following GW0742 treatment is used to 
fuel proliferation, as proliferative activity was not affected by GW0742 treatment (as discussed above), and would 
not be expected to play a significant role over the time-frame of the tube-formation assay (16 h).
Understanding the role of FAO in facilitating GW0742-induced tubulogenesis was made challenging by the 
tight relationship that exists between the PPARβ/δ signalling pathway and FAO. Variable responses by HUVEC 
to the generic CPT inhibitor, ETO, made the pharmacological approach unreliable. However, when attempts 
were made to silence CPT1A, this led to a concomitant reduction in PPARβ/δ gene expression. Despite attempts 
to measure PPARβ/δ protein, by both western blotting and immunofluorescence analysis, the lack of reliable, 
commercially available PPARβ/δ-selective antibodies50 meant that protein levels could not be reliably assessed. 
Despite not being able to perform tube-formation assays in CPT1A-silenced cells, it is tempting to suggest that 
such a reciprocal regulatory relationship between PPARβ/δ and CPT1A is an integral part of GW0742-induced 
tubulogenesis, where CPT1A-driven FAO influences PPARβ/δ transcriptional activity and possibly PPARβ/δ 
expression itself. Indeed, a similar association has been described in lymphatic ECs for the transcription fac-
tor PROX151. CPT1A is a PROX1 target and CPT1A-driven FAO provides acetyl-CoA that can be utilised for 
acetylation-mediated epigenetic modifications that facilitate the transcriptional activity of PROX1 and its target 
genes51. Any such molecular interaction with PPARβ/δ, however, requires further investigation.
It is important to note that the increase in FAO by GW0742 is not at the expense of glucose metabolism, as 
glucose oxidation and glycolysis were maintained, the latter even slightly increasing, thereby contrasting with the 
response in EC monolayers. The advantage that glycolysis holds for facilitating motile behaviour has been out-
lined above and its importance is highlighted by the cytostatic effect observed following inhibition of glycolysis 
with the PFKFB3 inhibitor, 3PO. This effect was independent of the stimulus used and is identical to the response 
observed by Schoors et al.19. Moreover, the reliance in particular on anaerobic glycolysis (even in the presence of 
sufficient oxygen) to support HUVEC growth and motility was indicated by the up-regulation of LDHA mRNA 
in both VEGF-A- and GW0742-stimulated cells and by the global impairment in tubulogenesis in the presence 
of the LDH inhibitor, oxamate. This requirement for LDH-facilitated anaerobic glycolysis has previously been 
described in pulmonary microvascular ECs in vitro and in vivo52,53. Although a baseline level of LDH-facilitated 
anaerobic glycolysis is essential, the extent to which it requires up-regulating to support tubulogenic activity is 
agonist-dependent, as maximal tubulogenesis induced by VEGF-A, which was also the largest inducer of glyc-
olytic flux, but not GW0742, was impaired when anaerobic glycolysis was maintained towards baseline levels 
through supplementing the culture medium with L-lactate. It is also worth noting that L-lactate alone exerted a 
pro-tubulogenic response, an effect also demonstrated by others54.
Together, these findings expand our knowledge of the role of PPARβ/δ within the endothelium by identifying 
a context-dependent regulation of EC metabolism in vitro by GW0742. In contrast to the glycolytic activation 
observed in VEGF-A-stimulated EC monolayers and dynamic cells (Fig. 7a), GW0742-activated PPARβ/δ pro-
motes a degree of metabolic quiescence in cell monolayers, but metabolic activation, in the form of elevated mito-
chondrial FAO, in tubulogenic cells (Fig. 7b). These actions are dependent on the metabolic co-regulator SIRT1. 
Further studies are now needed to decipher the specific interaction between these two metabolic regulators, as 
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well as the functional role of GW0742-induced FAO within the angiogenic process, with a view to exploit these 
findings for therapeutic intervention.
Methods
The data sets generated during the current study are available from the corresponding author on reasonable 
request.
cell isolation and culture. Human umbilical cord collection (obtained with informed written consent) 
and use of human endothelial cells conformed to the principles outlined in the Declaration of Helsinki and is 
approved by the NHS Health Research Authority East of England-Cambridge South Research Ethics Committee 
(REC reference 16/EE/0396). All experiments were performed in accordance with relevant guidelines and regu-
lations. Human umbilical vein endothelial cells (HUVEC) were isolated and cultured as described previously and 
were used between passage 2 and 455. Cells were cultured on 1% gelatin and maintained in M199 growth medium 
(M199 containing endothelial cell growth factor (20 μg/ml) and 20% (v/v) FBS). Experiments were performed in 
HEPES-buffered M199 containing 5mM L-glucose, 5mM L-glutamine, 1% FBS and 1% penicillin/streptomycin.
Endothelial cells were isolated from mouse hearts and gene expression analysed by reverse transcription 
quantitative PCR (RT-qPCR). All animal work was conducted according to national and international guidelines 
and was approved by the local ethics committee (Comité Institutionnel d‘Éthique Pour l’Animal de Laboratoire 
Azur, agreement number: PEA-NCE/2013/106). Age- and sex-matched tamoxifen-inducible Cre-mediated 
vascular-specific PPARβ/δ overexpressing animals (Tie2 CreERT2;PPARβ/δ) were injected for one week intra-
peritoneally either with sunflower oil (vehicle) or tamoxifen dissolved in sunflower oil (33 mg/kg per day), as 
previously described17. Tie2-CreERT2 animals injected with tamoxifen served as an additional control. Following 
terminal anaesthesia, hearts were excised, and cardiac endothelial cells were isolated by magnetic-activated cell 
sorting (MACS) using anti-CD31 beads (Miltenyi Biotec) prior to analysis by RT-qPCR.
tube formation assay. Tubulogenesis was assessed using the thin-layer angiogenesis (TLA) assay described 
previously55. Briefly, 5 μl/cm2 of GeltrexTM basement matrix (ThermoFisher Scientific; UK) was spread evenly on 
to wells of 24- or 96-well plates as appropriate. HUVEC were seeded (25,000 cells/cm2) in technical duplicate 
(24-well plate) or sextuplet (96-well plate) and incubated for 16 h in the presence or absence of compounds of 
interest. Phase-contrast images (24-well plate: 4 images/well; 96-well plate: 1 image/well) were acquired using a 
Leica DMIRB inverted microscope (10x objective (NA = 0.25)) controlled through Axiovision software version 
Figure 7. Schematic summary of VEGF-A- and GW0742-induced metabolic activation in dynamic HUVEC. 
(a) Treatment with VEGF-A is characterised by a significantly high rate of glycolysis which provides ATP for 
migration and activation of biosynthetic side-pathways for proliferation. At the same time, mitochondrial fatty 
acid oxidation (FAO) is maintained, which may further support proliferation through acting as an additional 
source of carbon. Key metabolites can also influence angiogenesis-related signalling pathways while Akt, 
through inhibitory phosphorylation, can inactivate the anti-proliferative transcription factor, FOXO1. (b) 
GW0742-induced tubulogenesis is SIRT1-dependent and characterised by a significant increase in 
mitochondrial FAO in addition to a moderate increase in glycolysis. Elevated acetyl-CoA levels may act as a 
substrate for post-translational protein acetylation (indicated in the figure by ) which could facilitate PPARβ/δ 
transcriptional activity and influence angiogenesis-related signalling pathways. FAO may also contribute to the 
regulation of EC permeability and thus may have a role in neovessel maturation/stabilisation. Thickness of 
arrows indicate increased flux while broken arrows indicate pathways that remain to be established.
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4.8.2 (Carl Zeiss Ltd; UK). For analysis, the mean number of branches per field was counted manually using 
ImageJ software.
Scratch wound migration. Scratch wound closure was assessed as previously described56. Confluent 
HUVEC monolayers on gelatin-coated 24-well plates in M199 growth medium (5% FBS) were wounded and 
non-adherent cells removed by washing in PBS followed by addition of fresh experimental medium contain-
ing compounds of interest as detailed in the figure legends. Phase-contrast images were obtained at time 0 and 
16 h (1 image/well) using a Leica DMIRB inverted microscope (10x objective (NA = 0.25)) controlled through 
Axiovision software version 4.8.2. Start and end gap distances were measured in pixels using ImageJ software and 
total migration after 16 h expressed as a percentage of control.
cell proliferation. HUVEC proliferation was quantified by nuclear staining (see Supplementary Methods) 
and by measuring 5-Bromo-2′-deoxyuridine (BrdU) incorporation. For BrdU incorporation experiments, 
HUVEC were seeded in triplicate on gelatin-coated 96-well plates (7,000 cells/well) in experimental medium 
supplemented with 10% FBS. The following day, cells were incubated with 10 µM BrdU (Sigma-Aldrich, UK) 
and compounds of interest for 4 hours in experimental medium. Cells were then fixed in 4% PFA for 10 min. 
Incorporated BrdU was detected by immunofluorescence using an anti-BrdU antibody (BioLegend, USA) and 
DAPI nuclear stain. Cells were imaged using a Leica DMIRB inverted microscope (20x objective). BrdU and 
DAPI positive nuclei were counted using the Analyze Particles function on ImageJ software. BrdU incorporation 
is given as the percentage of DAPI-positive nuclei which were BrdU-positive.
Small interfering RNA (siRNA). HUVEC were transfected in Opti-MEM transfection medium containing 
carnitine palmitoyltransferase-1A (CPT1A) targeting siRNAs (10 nM) obtained from Dharmacon/GE healthcare 
(ON-TARGET plus SMART pool) (siRNA 1) or Sigma Aldrich (siRNA ID: SASI_Hs01_00231321) (siRNA 2), 
pre-complexed with Lipofectamine RNAiMAX lipid carrier (ThermoFisher Scientific; UK) according to the man-
ufacturer’s instructions. For all experiments, control wells/dishes containing cells transfected with non-coding 
control pool (10 nM) (Dharmacon; UK) were run in parallel. Plates were incubated for 24 h (37 °C/5% CO2) 
before replacing the transfection medium with M199 growth medium. Cells were used for experiments 48 h 
post-transfection. Knockdown was assessed by RT-qPCR, immunocytochemistry and western blotting.
Reverse transcription-quantitative pcR (Rt-qpcR). Total RNA was extracted from cells using the 
Qiagen RNeasy Plus Mini Kit according to the manufacturer’s instructions. Complementary DNA (cDNA) was 
synthesised by the reverse transcription (RT) of mRNA using Oligo(dT) priming and SuperScriptTM II Reverse 
Transcriptase (ThermoFisher Scientific; UK). Quantitative PCR (qPCR), using both intercalator (SYBR® Premix 
Ex Taq™; Clontech: TaKara Bio) and probe-based (TaqManTM) technologies, was performed to determine changes 
in gene expression. CPT1A (Hs00912671_m1) and PPARβ/δ (Hs00606407_m1) TaqManTM primer-probes were 
obtained from Applied Biosystems (ThermoFisher Scientific; UK). All other primer sequences were designed 
using Primer3 and NCBI primer-BLAST software or obtained from published literature (see Supplementary 
Table S1). Minus cDNA template and H2O only controls were included for each gene of interest per experiment. 
Analysis was performed using the 2−ΔΔCt method with results normalised to β-actin or TATA-box binding pro-
tein (TBP) internal control gene.
Western blotting. Cells were lysed in RIPA buffer, supplemented with SigmaFastTM protease and phos-
phatase inhibitors (Sigma Aldrich; UK), and protein concentration was determined by the Pierce BCA Protein 
Assay (ThermoFisher Scientific; UK). Protein samples (30 µg) were separated by SDS-PAGE at 150 V on 10% 
Tris-Glycine mini gels (ThermoFisher Scientific, UK) for 60–90 min. Resolved proteins were transferred to 
HybondTM polyvinylidene difluoride (PVDF) membrane (0.45 µm; GE Healthcare; UK) by semi-dry transfer 
(0.8 mAmps/cm2). Membranes were blocked (5% milk or 2.5% BSA; 1 h) and probed with primary antibodies at 
4 °C overnight (anti-β-actin 1:5000 (Sigma Aldrich; UK); anti-FOXO1 1:1000; anti-pFOXO1 1:500; anti-CPT1A 
1:1000 (Cell Signaling Technology; UK)) followed by incubation with HRP-conjugated secondary antibodies 
(1:10,000 in 0.2% BSA; 1 h (ThermoFisher Scientific; UK). Proteins were detected by enhanced chemilumines-
cence (ECL) using Western Lightning plus ECL reagent (Perkin-Elmer; UK). Band densities were semi-quantified 
by densitometry performed using ImageJ software and normalised to β-actin loading control.
immunocytochemistry. Cells were fixed in 4% PFA (10–15 min) and permeabilised in 0.1% Triton-X in 
PBS-Tween (15 min). Cells were incubated in blocking buffer (3% BSA/1% goat serum; 40 min) prior to incuba-
tion with primary antibody (1% BSA/1% serum in PBS-Tween) at optimised concentrations (anti-SIRT1 1:250 
(MERK Millipore; UK); anti-acetylated-FOXO1 1:100 (Santa Cruz Biotechnology; Germany); anti-CPT1A 1:300 
(Cell Signaling Technology; UK)). Primary antibodies were detected with Alexa-Fluor 488 or Alexa-Fluor 594 
secondary antibodies (1:1000 (ThermoFisher Scientific; UK)). Samples were then incubated with DAPI (1:5000 
in TBS-Tween) for 5 min or coverslips were mounted using Fluoroshield DAPI-containing mounting medium 
(Sigma Aldrich; UK). Images were collected using either a DM4000B upright microscope (filter cubes A4 & L5 
(Leica Microsystems)) or a Leica DMIRB inverted microscope (40x objective) controlled through Axiovision 
software version 4.8.2 (Carl Zeiss Ltd; UK). Change in fluorescence intensity was measured in pixels using ImageJ 
software.
Metabolic analysis. Confluent HUVEC on gelatin-coated 24-well plates (for monolayer experiments) or 
HUVEC seeded onto GeltrexTM-coated 24-well plates at 25,000 cells/cm2 (for tube formation experiments) were 
incubated with or without compounds of interest for 4 or 5 h. Glycolytic rate was determined by measuring the 
production of 3H2O from 5–3H-glucose (17 MBq/mmol), separated using Dowex-1-Borate chromatography57. 
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Change in the rate of FAO was determined by the production of 3H2O from 9,10–3H-palmitate (final specific 
activity 0.0185 MBq/ml), measured following separation of 3H2O by chloroform:methanol Folch extraction58. 
Glucose oxidation was measured by 14CO2-capture using D-U-14C-glucose (Perkin-Elmer; UK) at a final spe-
cific activity of 0.00925 MBq/ml59. Radioactivity was determined in technical duplicate using a Tri-carb 2800TR 
Liquid Scintillation Analyser and results calculated as nmol of substrate/minute/105 cells.
Estimated ATP production was calculated from the rate of glycolysis, glucose oxidation and FAO. It was 
assumed that 2 moles of ATP were generated per mole of glucose that underwent glycolysis, 31 moles of ATP 
generated per mole of glucose oxidised and 106 moles of ATP generated per mole of fatty acid (palmitate) oxi-
dised. Relative cellular ATP content was measured in EC monolayers using the CellTitre-Glo 2.0 assay kit from 
Promega, according to the manufacturer’s instructions.
Cellular oxygen consumption rate (OCR) was measured in EC monolayers using the Seahorse XFp extracel-
lular flux analyzer (Agilent Technologies, UK). Baseline OCR was measured over a 30 min period with readings 
taken at 5 min intervals. GW0742 (100 nM) or medium alone was automatically injected into the appropriate 
wells and OCR was measured at 15 min intervals up to 4 h post-treatment.
Mitochondrial activity. Overall mitochondrial activity was assessed by 3-(4,5 dimethylthiazol-2-yl)-2
,5-diphenyltetrazolium bromide (MTT) reduction assay. After treatment, cells were incubated for 2 h (37 °C/5% 
CO2) with MTT solution (1 mg/ml in PBS) and the resultant formazan product was solubilised using solubilisa-
tion solution (DMSO; 37 °C; 20 min). Solubilisation solution was collected and transferred to a clear 96-well plate 
(50 µl/well in technical triplicate) prior to measurement of absorbance at 550 nm. Readings were corrected for 
background and results are expressed as a percentage of control.
Statistical analysis. All data are expressed as means ± standard error of means (S.E.M) and unless stated 
otherwise, are from at least 3 independent experiments performed on separate EC isolates. Data analysis was 
performed using GraphPad Prism 6 software. Student’s t-test was employed for establishing significant differences 
between two groups. For the comparison of three or more groups analysis of variance (ANOVA) was applied 
followed by Bonferroni or Tukey post-hoc analysis as appropriate. In all cases, p < 0.05 was used to indicate sta-
tistical significance.
Received: 26 September 2019; Accepted: 7 April 2020;
Published: xx xx xxxx
References
 1. Herbert, S. P. & Stainier, D. Y. R. Molecular control of endothelial cell behaviour during blood vessel morphogenesis. Nature Reviews 
Molecular Cell Biology 12, 551–564 (2011).
 2. Vander Heiden, M. G. et al. Metabolic Pathway Alterations that Support Cell Proliferation. Cold Spring Harbor Symposia on 
Quantitative Biology 76, 325–334 (2011).
 3. De Bock, K. et al. Role of PFKFB3-Driven Glycolysis in Vessel Sprouting. Cell 154, 651–663 (2013).
 4. Patella, F. et al. Proteomics-Based Metabolic Modeling Reveals That Fatty Acid Oxidation (FAO) Controls Endothelial Cell (EC) 
Permeability. Molecular & Cellular Proteomics 14, 621–634 (2015).
 5. Schoors, S. et al. Fatty acid carbon is essential for dNTP synthesis in endothelial cells. Nature 520, 192–197 (2015).
 6. Ward, P. S. & Thompson, C. B. Signaling in Control of Cell Growth and Metabolism. Cold Spring Harbor Perspectives in Biology 4 
(2012).
 7. Piqueras, L. et al. Activation of PPAR beta/delta Induces Endothelial Cell Proliferation and Angiogenesis. Arteriosclerosis, 
thrombosis, and vascular biology 27, 63–69 (2007).
 8. Wagner, N. et al. Peroxisome proliferator-activated receptor β stimulation induces rapid cardiac growth and angiogenesis via direct 
activation of calcineurin. Cardiovascular research 83, 61–71 (2009).
 9. Khazaei, M., Salehi, E., Rashidi, B., Javanmard, S. H. & Fallahzadeh, A. R. Role of peroxisome proliferator-activated receptor β 
agonist on angiogenesis in hindlimb ischemic diabetic rats. Journal of Diabetes and its Complications 26, 137–140 (2012).
 10. Capozzi, M. E., McCollum, G. W., Savage, S. R. & Penn, J. S. Peroxisome Proliferator-Activated Receptor-β/δ Regulates Angiogenic 
Cell Behaviors and Oxygen-Induced Retinopathy. Investigative Ophthalmology & Visual Science 54, 4197–4207 (2013).
 11. Wang, Y.-X. et al. Regulation of Muscle Fiber Type and Running Endurance by PPARδ. Plos Biol 2, e294 (2004).
 12. Cheng, L. et al. Cardiomyocyte-restricted peroxisome proliferator-activated receptor-δ deletion perturbs myocardial fatty acid 
oxidation and leads to cardiomyopathy. Nature medicine 10, 1245–1250 (2004).
 13. Tanaka, T. et al. Activation of peroxisome proliferator-activated receptor δ induces fatty acid β-oxidation in skeletal muscle and 
attenuates metabolic syndrome. Proceedings of the National Academy of Sciences 100, 15924-15929, https://doi.org/10.1073/
pnas.0306981100 (2003).
 14. Toral, M. et al. Carnitine palmitoyltransferase-1 up-regulation by PPAR-β/δ prevents lipid-induced endothelial dysfunction. Clinical 
science 129, 823–837 (2015).
 15. Sznaidman, M. L. et al. Novel selective small molecule agonists for peroxisome proliferator-activated receptor δ (PPARδ)—synthesis 
and biological activity. Bioorganic & Medicinal Chemistry Letters 13, 1517–1521 (2003).
 16. Harrington, L. S. et al. The PPARβ/δAgonist GW0742 Relaxes Pulmonary Vessels and Limits Right Heart Hypertrophy in Rats with 
Hypoxia-Induced Pulmonary Hypertension. Plos one 5, e9526 (2010).
 17. Wagner, K.-D., Vukolic, A., Baudouy, D., Michiels, J.-F. & Wagner, N. Inducible Conditional Vascular-Specific Overexpression of 
Peroxisome Proliferator-Activated Receptor Beta/Delta Leads to Rapid Cardiac Hypertrophy. PPAR research 2016, 12 (2016).
 18. Krützfeldt, A., Spahr, R., Mertens, S., Siegmund, B. & Piper, H. M. Metabolism of exogenous substrates by coronary endothelial cells 
in culture. Journal of Molecular and Cellular Cardiology 22, 1393–1404 (1990).
 19. Schoors, S. et al. Partial and Transient Reduction of Glycolysis by PFKFB3 Blockade Reduces Pathological Angiogenesis. Cell 
metabolism 19, 37–48 (2014).
 20. Wright, G. L. et al. VEGF stimulation of mitochondrial biogenesis: requirement of AKT3 kinase. FASEB journal: official publication 
of the Federation of American Societies for Experimental Biology 22, 3264–3275 (2008).
 21. Wang, P. et al. Peroxisome Proliferator-Activated Receptor δ Is an Essential Transcriptional Regulator for Mitochondrial Protection 
and Biogenesis in Adult Heart. Circulation research 106, 911–919 (2010).
 22. Kim, M. Y. et al. The PPARδ-mediated inhibition of angiotensin II-induced premature senescence in human endothelial cells is 
SIRT1-dependent. Biochemical Pharmacology 84, 1627–1634 (2012).
1 4Scientific RepoRtS |         (2020) 10:7849  | https://doi.org/10.1038/s41598-020-63900-0
www.nature.com/scientificreportswww.nature.com/scientificreports/
 23. Potente, M. et al. SIRT1 controls endothelial angiogenic functions during vascular growth. Genes & development 21, 2644–2658 
(2007).
 24. Guarani, V. et al. Acetylation-dependent regulation of endothelial Notch signalling by the SIRT1 deacetylase. Nature 473, 234–238 
(2011).
 25. Wilhelm, K. et al. FOXO1 couples metabolic activity and growth state in the vascular endothelium. Nature 529, 216–220 (2016).
 26. Dormond, O., Madsen, J. C. & Briscoe, D. M. The Effects of mTOR-Akt Interactions on Anti-apoptotic Signaling in Vascular 
Endothelial Cells. Journal of Biological Chemistry 282, 23679–23686 (2007).
 27. Potente, M. et al. Involvement of Foxo transcription factors in angiogenesis and postnatal neovascularization. The Journal of Clinical 
Investigation 115, 2382–2392, https://doi.org/10.1172/JCI23126 (2005).
 28. Hoeben, A. et al. Vascular Endothelial Growth Factor and Angiogenesis. Pharmacological Reviews 56, 549–580 (2004).
 29. Park, J.-H. et al. The PPARδ ligand L-165041 inhibits vegf-induced angiogenesis, but the antiangiogenic effect is not related to 
PPARδ. Journal of cellular biochemistry 113, 1947–1954 (2012).
 30. Kim, J.-B., Lee, S. H., Ahn, J. & Kim, J. The Peroxisome Proliferator-Activated Receptor δ Agonist, GW501516, Inhibits Angiogenesis 
through Dephosphorylation of Endothelial Nitric Oxide Synthase. J Lipid Atheroscler 1, 11–20 (2012).
 31. Stephen, R. L. et al. Activation of Peroxisome Proliferator-Activated Receptor δ Stimulates the Proliferation of Human Breast and 
Prostate Cancer Cell Lines. Cancer research 64, 3162–3170 (2004).
 32. Yu, C.-W. et al. Dual role of fatty acid-binding protein 5 on endothelial cell fate: a potential link between lipid metabolism and 
angiogenic responses. Angiogenesis 19, 95–106 (2016).
 33. Treps, L., Conradi, L.-C., Harjes, U. & Carmeliet, P. Manipulating Angiogenesis by Targeting Endothelial Metabolism: Hitting the 
Engine Rather than the Drivers—A New Perspective? Pharmacological Reviews 68, 872–887 (2016).
 34. Vizán, P. et al. Characterization of the metabolic changes underlying growth factor angiogenic activation: identification of new 
potential therapeutic targets. Carcinogenesis 30, 946–952 (2009).
 35. Fan, Y. et al. Suppression of Pro-inflammatory Adhesion Molecules by PPAR-δ in Human Vascular Endothelial Cells. Arteriosclerosis, 
thrombosis, and vascular biology 28, 315–321 (2008).
 36. Piqueras, L. et al. Activation of PPARβ/δ inhibits leukocyte recruitment, cell adhesion molecule expression, and chemokine release. 
Journal of Leukocyte Biology 86, 115–122 (2009).
 37. Jiang, B., Liang, P., Zhang, B., Huang, X. & Xiao, X. Enhancement of PPAR-β activity by repetitive low-grade H2O2 stress protects 
human umbilical vein endothelial cells from subsequent oxidative stress-induced apoptosis. Free Radical Biology and Medicine 46, 
555–563 (2009).
 38. Ali, F. et al. PPARδ and PGC1α act cooperatively to induce haem oxygenase-1 and enhance vascular endothelial cell resistance to 
stress. Cardiovascular research 85, 701–710 (2010).
 39. Dobrina, A. & Rossi, F. Metabolic properties of freshly isolated bovine endothelial cells. Biochimica et Biophysica Acta (BBA) - 
Molecular Cell Research 762, 295–301 (1983).
 40. Coppiello, G. et al. Meox2/Tcf15 Heterodimers Program the Heart Capillary Endothelium for Cardiac Fatty Acid Uptake. Circulation 
131, 815–826 (2015).
 41. Letavernier, E. et al. Peroxisome Proliferator-Activated Receptor β/δ Exerts a Strong Protection from Ischemic Acute Renal Failure. 
Journal of the American Society of Nephrology 16, 2395–2402 (2005).
 42. Kapoor, A., Collino, M., Castiglia, S., Fantozzi, R. & Thiemermann, C. Activation of peroxisome proliferator-activated receptor-beta/
delta attenuates myocardial ischemia/reperfusion injury in the rat. Shock 34, 117–124 (2010).
 43. Chao, X. et al. Activation of Peroxisome Proliferator–activated Receptor β/δ Attenuates Acute Ischemic Stroke on Middle Cerebral 
Ischemia Occlusion in Rats. Journal of Stroke and Cerebrovascular Diseases 23, 1396–1402 (2014).
 44. Doddaballapur, A. et al. Laminar Shear Stress Inhibits Endothelial Cell Metabolism via KLF2-Mediated Repression of PFKFB3. 
Arteriosclerosis, thrombosis, and vascular biology 35, 137–145 (2015).
 45. Gerhart-Hines, Z. et al. Metabolic control of muscle mitochondrial function and fatty acid oxidation through SIRT1/PGC-1α. The 
EMBO Journal 26, 1913–1923, https://doi.org/10.1038/sj.emboj.7601633 (2007).
 46. Battegay, E. J., Rupp, J., Iruela-Arispe, L., Sage, E. H. & Pech, M. PDGF-BB modulates endothelial proliferation and angiogenesis in 
vitro via PDGF beta-receptors. The Journal of cell biology 125, 917–928 (1994).
 47. Mattagajasingh, I. et al. SIRT1 promotes endothelium-dependent vascular relaxation by activating endothelial nitric oxide synthase. 
Proceedings of the National Academy of Sciences 104, 14855–14860 (2007).
 48. Dranka, B. P., Hill, B. G. & Darley-Usmar, V. M. Mitochondrial reserve capacity in endothelial cells: The impact of nitric oxide and 
reactive oxygen species. Free radical biology & medicine 48, 905–914 (2010).
 49. Satake, S. et al. Up-regulation of vascular endothelial growth factor in response to glucose deprivation. Biology of the Cell 90, 
161–168 (1998).
 50. Giordano Attianese, G. M. & Desvergne, B. Integrative and systemic approaches for evaluating PPARbeta/delta (PPARD) function. 
Nuclear receptor signaling 13, e001 (2015).
 51. Wong, B. W. et al. The role of fatty acid β-oxidation in lymphangiogenesis. Nature 542, 49–54 (2017).
 52. Parra-Bonilla, G., Alvarez, D. F., Al-Mehdi, A.-B., Alexeyev, M. & Stevens, T. Critical role for lactate dehydrogenase A in aerobic 
glycolysis that sustains pulmonary microvascular endothelial cell proliferation. American Journal of Physiology - Lung Cellular and 
Molecular Physiology 299, L513–L522 (2010).
 53. Parra-Bonilla, G., Alvarez, D. F., Alexeyev, M., Vasauskas, A. & Stevens, T. Lactate Dehydrogenase A Expression Is Necessary to 
Sustain Rapid Angiogenesis of Pulmonary Microvascular Endothelium. Plos one 8, e75984 (2013).
 54. Hunt, T. K. et al. Aerobically derived lactate stimulates revascularization and tissue repair via redox mechanisms. Antioxidants & 
redox signaling 9, 1115–1124 (2007).
 55. Faulkner, A. et al. A thin layer angiogenesis assay: a modified basement matrix assay for assessment of endothelial cell differentiation. 
BMC Cell Biology 15, 41 (2014).
 56. Pula, G. et al. Paracrine Stimulation of Endothelial Cell Motility and Angiogenesis by Platelet-Derived Deoxyribose-1-Phosphate. 
Arteriosclerosis, thrombosis, and vascular biology 30, 2631–2638 (2010).
 57. Hammerstedt, R. H. The use of dowex-1-borate to separate 3HOH from 2-3H-glucose. Analytical Biochemistry 56, 292–293 (1973).
 58. Lopaschuk, G. D. & Barr, R. L. Measurements of fatty acid and carbohydrate metabolism in the isolated working rat heart. Mol Cell 
Biochem 172, 137–147 (1997).
 59. Board, M. et al. Acetoacetate is a more efficient energy-yielding substrate for human mesenchymal stem cells than glucose and 
generates fewer reactive oxygen species. The International Journal of Biochemistry & Cell Biology 88, 75–83 (2017).
Acknowledgements
The authors would like to acknowledge Elaine Shervill for her technical assistance with HUVEC isolation and 
Dr Andrew Hibbert for providing support in microscopy. The work was supported in part by the Biotechnology 
and Biosciences Research Council (to CW-J): BB/I005862/1; BB/J50015X/1. Data presented in Figure 3j were 
supported by the French Government (National Research Agency, ANR) through the “Investments for the 
Future” LABEX SIGNALIFE program (reference ANR-11-LABX-0028–01), the Association pour la Recherche 
1 5Scientific RepoRtS |         (2020) 10:7849  | https://doi.org/10.1038/s41598-020-63900-0
www.nature.com/scientificreportswww.nature.com/scientificreports/
sur le Cancer, Plan Cancer INSERM, Fondation pour la Recherche Médicale, and Fondation de France (KDW), 
and the Association pour la Recherche sur le Cancer and Gemluc (NW).
Author contributions
A.F. conceived the study, designed and performed the majority of experiments, analysed and interpreted the 
data, and wrote the manuscript. E.L., R.P. and C.J. contributed to aspects of the data sets shown by performing 
experiments. C.L., M.B. and C.C. provided expertise in metabolic analysis and assisted with experiments. 
K.D.W. and N.W. performed the PCR analysis of cells from the mouse lines generated in their laboratory. C.W.-J. 
conceived the study, designed experiments, contributed to ongoing research and data interpretation, and wrote 
the manuscript. All authors reviewed and agreed the final manuscript.
competing interests
The authors declare no competing interests.
Additional information
Supplementary information is available for this paper at https://doi.org/10.1038/s41598-020-63900-0.
Correspondence and requests for materials should be addressed to C.W.-J.
Reprints and permissions information is available at www.nature.com/reprints.
Publisher’s note Springer Nature remains neutral with regard to jurisdictional claims in published maps and 
institutional affiliations.
Open Access This article is licensed under a Creative Commons Attribution 4.0 International 
License, which permits use, sharing, adaptation, distribution and reproduction in any medium or 
format, as long as you give appropriate credit to the original author(s) and the source, provide a link to the Cre-
ative Commons license, and indicate if changes were made. The images or other third party material in this 
article are included in the article’s Creative Commons license, unless indicated otherwise in a credit line to the 
material. If material is not included in the article’s Creative Commons license and your intended use is not per-
mitted by statutory regulation or exceeds the permitted use, you will need to obtain permission directly from the 
copyright holder. To view a copy of this license, visit http://creativecommons.org/licenses/by/4.0/.
 
© The Author(s) 2020
